Diquafosol is a medication used to treat dry eye syndrome by increasing tear production. However, during the manufacturing process, impurities may be introduced which can affect the purity and potency of the medication. These impurities can include residual solvents, degradation products, and other related substances. The presence of these impurities can impact the safety and efficacy of the drug and must be closely monitored and controlled during production.
